Erramouspe PJ, García‐Pintos MF, Benipal S, et al. - This study was undertaken to investigate patient characteristics, tranexamic acid (TXA) dosing strategies, and the incidence of mortality and adverse events in adult trauma patients receiving TXA at a U.S. Level I trauma center in the post–CRASH‐2 era. Between July 2014 and June 2017, a retrospective study was conducted including patients aged 18 years or older who received TXA after an acute injury. Data were obtained by trained abstractors from the trauma registry and hospital electronic medical records. The primary endpoints included in‐hospital death and acute thromboembolic events within 28 days from injury. A total of 273 patients with a mean (±SD) age of 43.8 (±18.7) years were included in the study. Compared with the CRASH‐2 trial, adult trauma patients receiving TXA had similar incidences of death but higher incidences of thromboembolic events. The study noted that change in patient characteristics, injury severity, TXA dosing, and surgery and transfusion rates could explain these observed differences. Future study is needed to serve additional insight into the incidence and risk factors of thromboembolic events in TXA use.